A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Stopped early · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Leiomyosarcoma
In brief
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Key facts
- Study ID
- NCT05269355
- Run by
- PTC Therapeutics
- People needed
- 359
- Starts
- 2022-05-23
- Expected to finish
- 2024-07-17
- Last updated by the study team
- 2025-06-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
- Sarcoma Oncology Research Center — Santa Monica, California, United States
- Stanford Cancer Center — Stanford, California, United States
- University of Colorado Denver — Denver, Colorado, United States
- Yale University — New Haven, Connecticut, United States
- Mayo Clinic — Jacksonville, Florida, United States
- University of Florida (UF) Health Cancer Center - Orlando Health — Orlando, Florida, United States
- Moffitt — Tampa, Florida, United States
- Northwestern Memorial Hospital — Chicago, Illinois, United States
- Northwestern Medicine - Warrenville Cancer Center — Warrenville, Illinois, United States
- Johns Hopkins Oncology Group — Baltimore, Maryland, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Washington University — St Louis, Missouri, United States
- The Trustees of Columbia University — New York, New York, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- The Ohio State University (OSU) — Columbus, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Chris O'Brien Lifehouse — Camperdown, Australia
- Peter MacCallum Cancer Institute — East Melbourne, Australia
- City of Hope — Duarte, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.